FIGURE 5.

KY19334 treatment increases energy expenditure. C57BL/6 mice fed NCD or HFD for 18 weeks were p.o. administered KY19334 (25 mg/kg/d) or sitagliptin (50 mg/kg/d) for 5 days on weeks 8 and 12 (n = 10 per group). (A) Representative images (three total images per group) of UCP1 immunohistochemistry in scWAT. (B, C) Relative mRNA expression levels of Wnt/β‐catenin signalling target genes (B), mitochondrial biogenesis and beige fat markers (C) were normalized by vehicle‐treated HFD mice group. (D) Oxygen consumption. (E) Carbon dioxide production. (F) Energy expenditure normalized for body mass (left panel). Correlation of energy expenditure by body mass using covariance (middle and right panel). (G) Cumulative ambulatory counts. (H) Respiratory exchange ratios. Scale bars = 100 μm. All data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 determined by Student's t‐test